Are there racial and ethnic disparities in the use of novel hormonal therapy agents in men with advanced prostate cancer?

Researchers assessed ethnic and racial differences in novel hormonal therapy (NHT) use among advanced prostate cancer (PCa) patients.

Dose Escalation With Infliximab Biosimilar Can Restore Responses in IBD

LAS VEGAS — In patients with inflammatory bowel disease who lost response after infliximab (Remicade) induction, escalating the maintenance dose of the subcutaneous infliximab biosimilar

February 3, 2024

The ethics of nanobiotechnology: A call for global regulation

Prosthetics moved by thoughts. Targeted treatments for aggressive brain cancer. Soldiers with enhanced vision or bionic ears.

July 13, 2023

UniQure sells Massachusetts manufacturing site to Genezen as it continues to downsize

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.